Milrinone Stragen

Milrinone, the active ingredient in Milrinone Stragen, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients, providing short‑term inotropic support and vasodilation to improve cardiac output.

GNH USA supplies Milrinone Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide. All batches are manufactured under EU GMP standards and shipped with appropriate temperature control.

Milrinone is used as an inotropic and vasodilator agent in acute cardiac conditions.

Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. Cardiogenic shock: provides inotropic support and systemic vasodilation to maintain organ perfusion. Post‑cardiac surgery low cardiac output syndrome: supports myocardial contractility during the immediate postoperative period.

Milrinone may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Arrhythmias: premature ventricular beats or tachycardia. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with skin reddening. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring intervention. - Ventricular arrhythmias: sustained tachyarrhythmias that may be life‑threatening. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Thrombocytopenia: marked reduction in platelet count. - Anaphylactic reactions: rare allergic responses requiring emergency care.

Milrinone should be administered with careful monitoring and consideration of patient‑specific factors.

Blood pressure monitoring: observe for hypotension and adjust infusion rate as needed. Cardiac rhythm surveillance: continuous ECG monitoring to detect arrhythmias. Renal function assessment: dose may need adjustment in severe renal impairment. Avoid in severe aortic stenosis: fixed outflow obstruction can worsen with vasodilation. Caution with concurrent vasodilators: risk of additive hypotensive effect. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations, raising toxicity risk. - Potent vasodilators (e.g., nitroglycerin): may precipitate profound hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response, requiring dose titration. - Digoxin: monitor serum levels as altered hemodynamics can affect digoxin pharmacodynamics.